Oruka Therapeutics (ORKA) Competitors $14.23 -0.31 (-2.13%) Closing price 04:00 PM EasternExtended Trading$14.24 +0.00 (+0.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ORKA vs. KNSA, TWST, CNTA, BEAM, CGON, DNLI, HRMY, IRON, MESO, and BLTEShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Kiniksa Pharmaceuticals International (KNSA), Twist Bioscience (TWST), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), CG Oncology (CGON), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), Disc Medicine (IRON), Mesoblast (MESO), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Oruka Therapeutics vs. Its Competitors Kiniksa Pharmaceuticals International Twist Bioscience Centessa Pharmaceuticals Beam Therapeutics CG Oncology Denali Therapeutics Harmony Biosciences Disc Medicine Mesoblast Belite Bio Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Which has more volatility & risk, KNSA or ORKA? Kiniksa Pharmaceuticals International has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500. Is KNSA or ORKA more profitable? Oruka Therapeutics has a net margin of 0.00% compared to Kiniksa Pharmaceuticals International's net margin of -3.52%. Kiniksa Pharmaceuticals International's return on equity of -3.83% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International-3.52% -3.83% -2.98% Oruka Therapeutics N/A -25.66%-23.39% Which has higher valuation & earnings, KNSA or ORKA? Kiniksa Pharmaceuticals International has higher revenue and earnings than Oruka Therapeutics. Kiniksa Pharmaceuticals International is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M4.64-$43.19M-$0.25-107.60Oruka TherapeuticsN/AN/A-$83.72M-$4.51-3.16 Do analysts rate KNSA or ORKA? Kiniksa Pharmaceuticals International presently has a consensus target price of $39.67, suggesting a potential upside of 47.46%. Oruka Therapeutics has a consensus target price of $40.38, suggesting a potential upside of 183.73%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Oruka Therapeutics is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Do institutionals & insiders have more ownership in KNSA or ORKA? 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer KNSA or ORKA? In the previous week, Oruka Therapeutics had 3 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 11 mentions for Oruka Therapeutics and 8 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.61 beat Oruka Therapeutics' score of 0.27 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 0 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKiniksa Pharmaceuticals International beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks. Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$544.39M$2.48B$5.67B$9.49BDividend YieldN/A1.80%4.05%4.00%P/E RatioN/A9.1127.9419.95Price / SalesN/A544.41396.5882.68Price / CashN/A166.9336.1958.45Price / Book1.315.228.635.82Net Income-$83.72M$30.99M$3.24B$258.42M7 Day Performance-7.36%4.29%3.22%1.94%1 Month Performance21.00%13.40%10.72%12.02%1 Year PerformanceN/A0.59%34.94%20.80% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics2.7729 of 5 stars$14.23-2.1%$40.38+183.7%N/A$544.39MN/A0.00N/ANews CoverageUpcoming EarningsAnalyst ForecastKNSAKiniksa Pharmaceuticals International3.4797 of 5 stars$28.42-2.1%$39.67+39.6%+3.2%$2.12B$423.24M-113.68220News CoveragePositive NewsAnalyst ForecastTWSTTwist Bioscience4.3598 of 5 stars$34.77-1.1%$50.40+45.0%-38.8%$2.11B$312.97M-10.70990Positive NewsCNTACentessa Pharmaceuticals3.3282 of 5 stars$16.06+2.4%$28.10+75.0%+57.8%$2.10B$6.85M-8.87200Analyst ForecastInsider TradeBEAMBeam Therapeutics2.2934 of 5 stars$21.03+1.3%$48.75+131.8%-26.9%$2.09B$63.52M-4.56510Analyst UpgradeAnalyst RevisionCGONCG Oncology2.5116 of 5 stars$26.90+0.6%$55.30+105.6%-23.3%$2.04B$1.14M-17.8161DNLIDenali Therapeutics4.1936 of 5 stars$13.83-1.2%$33.71+143.8%-39.4%$2.03BN/A-5.18430Upcoming EarningsHRMYHarmony Biosciences4.8366 of 5 stars$35.25+0.1%$51.00+44.7%+11.1%$2.02B$714.73M13.45200Positive NewsAnalyst ForecastAnalyst RevisionIRONDisc Medicine3.3742 of 5 stars$59.38+2.8%$95.73+61.2%+32.1%$2.00BN/A-15.1530Analyst ForecastMESOMesoblast0.9153 of 5 stars$14.65-6.2%$18.00+22.9%+94.6%$2.00B$5.67M0.0080Upcoming EarningsGap UpBLTEBelite Bio1.7601 of 5 stars$61.30+0.6%$96.67+57.7%+24.4%$1.94BN/A-45.0710 Related Companies and Tools Related Companies KNSA Competitors TWST Competitors CNTA Competitors BEAM Competitors CGON Competitors DNLI Competitors HRMY Competitors IRON Competitors MESO Competitors BLTE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORKA) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORKA Stock Alerts